The cellular basis of tumor progression - PubMed (original) (raw)
Review
The cellular basis of tumor progression
G H Heppner et al. Int Rev Cytol. 1998.
Abstract
Variability in disease presentation and course is a hallmark of cancer. Variability is seen among similarly diagnosed cancers in different patients or animal hosts and in the same cancer at different periods of time. This latter type of variability, termed "tumor progression," was defined by Foulds in a series of six rules that describe the independent behavior of individual cancers and the independent evolution of different cancer characteristics. Tumor progression is believed to result from variability among subpopulations of tumor cells within individual cancers and from selection of these subpopulations by conditions within the cancer environment, such that different subpopulations come to prominence over the course of cancer development and growth. Interactions among subpopulations, however, modulate tumor behavior as well as tumor evolution. The leading hypothesis for the origin of tumor subpopulations is the genetic instability of cancer cells. There are a number of possible mechanisms of genetic instability, some internal to cancer cells (mutation, amplification, mutator phenotypes, DNA repair deficiencies) and some present in the tumor microenvironment (endogenous mutagens). There are also potential epigenetic mechanisms of variability, including alterations in gene regulation, differentiation, adaptation, and cell fusion. Regardless of mechanism, the heterogeneity of tumor subpopulations poses a number of challenges to the practice of cancer research, including the design of reproducible and meaningful experiments. Tumor heterogeneity also has significant consequences for the clinical assessment of tumor prognosis and the development of effective treatment regimens.
Similar articles
- Tumor heterogeneity and immunotherapy of cancer.
Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S, Warnaar SO. Fleuren GJ, et al. Immunol Rev. 1995 Jun;145:91-122. doi: 10.1111/j.1600-065x.1995.tb00078.x. Immunol Rev. 1995. PMID: 7590832 Review. - Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.
Scanlon SE, Glazer PM. Scanlon SE, et al. DNA Repair (Amst). 2015 Aug;32:180-189. doi: 10.1016/j.dnarep.2015.04.030. Epub 2015 May 1. DNA Repair (Amst). 2015. PMID: 25956861 Free PMC article. Review. - An experimental model for oncogene activation during tumor progression in vivo.
Garte SJ, Burns FJ, Ashkenazi-Kimmel T, Cosma GN, Sawey MJ. Garte SJ, et al. Anticancer Res. 1989 Sep-Oct;9(5):1439-46. Anticancer Res. 1989. PMID: 2686538 Review. - Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment.
Sun XX, Yu Q. Sun XX, et al. Acta Pharmacol Sin. 2015 Oct;36(10):1219-27. doi: 10.1038/aps.2015.92. Epub 2015 Sep 21. Acta Pharmacol Sin. 2015. PMID: 26388155 Free PMC article. Review. - Somatic clonal evolution: A selection-centric perspective.
Scott J, Marusyk A. Scott J, et al. Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):139-150. doi: 10.1016/j.bbcan.2017.01.006. Epub 2017 Feb 2. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28161395 Review.
Cited by
- Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses.
Monaco ML, Idris OA, Essani K. Monaco ML, et al. Cancers (Basel). 2023 Apr 21;15(8):2393. doi: 10.3390/cancers15082393. Cancers (Basel). 2023. PMID: 37190321 Free PMC article. Review. - Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer.
Padole A, Singh R, Zhang EW, Mendoza DP, Dagogo-Jack I, Kalra MK, Digumarthy SR. Padole A, et al. Transl Lung Cancer Res. 2020 Aug;9(4):1441-1451. doi: 10.21037/tlcr-20-347. Transl Lung Cancer Res. 2020. PMID: 32953516 Free PMC article. - Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
Wang R, Lewis MS, Lyu J, Zhau HE, Pandol SJ, Chung LWK. Wang R, et al. Prostate. 2020 Feb;80(3):274-283. doi: 10.1002/pros.23941. Epub 2019 Dec 17. Prostate. 2020. PMID: 31846114 Free PMC article. - Thyroid hormone induces progression and invasiveness of squamous cell carcinomas by promoting a ZEB-1/E-cadherin switch.
Miro C, Di Cicco E, Ambrosio R, Mancino G, Di Girolamo D, Cicatiello AG, Sagliocchi S, Nappi A, De Stefano MA, Luongo C, Antonini D, Visconte F, Varricchio S, Ilardi G, Del Vecchio L, Staibano S, Boelen A, Blanpain C, Missero C, Salvatore D, Dentice M. Miro C, et al. Nat Commun. 2019 Nov 27;10(1):5410. doi: 10.1038/s41467-019-13140-2. Nat Commun. 2019. PMID: 31776338 Free PMC article. - Defining the Hallmarks of Metastasis.
Welch DR, Hurst DR. Welch DR, et al. Cancer Res. 2019 Jun 15;79(12):3011-3027. doi: 10.1158/0008-5472.CAN-19-0458. Epub 2019 May 3. Cancer Res. 2019. PMID: 31053634 Free PMC article. Review.